Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

State guide

Nebraska Medicaid and GLP-1s

Published by Telehealth Graded · Updated

The takeaway

Nebraska Medicaid's Wegovy form is revised by its drug review board in open session, including a liver-disease use added in January 2026.

Reading the state documents

Look for Nebraska's position on these drugs where the state publishes policy and you will come away empty. Thirty provider bulletins across 2025 and 2026 do not name a single one of them. The record is in the minutes of the Medicaid drug utilization review board, which meets four times a year in a Lincoln hotel, revises the Wegovy authorization form, and writes to prescribers about what these drugs are being combined with.

3
documents cited
6
sourced facts
3
primary sources

What changed, and what the document says

  1. What the board changed in January

    Context

    A liver-disease indication was added to a form that already existed, which tells you the drug was already being authorized for something.

    “Dianne Garside presented the Wegovy PA form. New indication criteria for MASH was added to the existing Wegovy PA form.”

    Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026

  2. The roll call

    Context

    Five members, five votes for, and a revision asked for from the floor before the vote was taken.

    “A motion to approve the form with revisions to differentiate the correct dosage forms with their indications was made by Titchener and approved as follows: Broucek-yes, Moore-yes, Randolph-yes, Timmons-yes, Titchener-yes.”

    Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026

  3. Who else was in the room

    Context

    The manufacturer of the drug under discussion spoke during the public comment item, and the minutes record it.

    “Novo-Nordisk representatives made comments regarding the presented Wegovy PA form.”

    Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026

  4. What the state is writing to prescribers about

    Context

    Nebraska's live GLP-1 project is a combination-safety letter campaign, and the board was given a response rate for it.

    “Lee Stutzman provided updates on letters sent to prescribers regarding concomitant prescribing of GLP-1s and DPP4s.”

    Nebraska Department of Health and Human Services, Medicaid Drug Utilization Review Board — Tuesday January 13th, 2026

  5. Where the criteria themselves are posted

    Context

    The bulletin that announces drug list changes directs readers to a contractor's site for the criteria. We could not verify the criteria document, so the bulletin alone does not establish its coverage requirements.

    “This provider bulletin is being issued to notify Medicaid providers of changes to the Nebraska Medicaid PDL, effective July 17, 2026.”

    Nebraska Department of Health and Human Services, Division of Medicaid and Long-Term Care — June 17, 2026

  6. The bill that would have settled it

    Context

    A 2024 bill would have required comprehensive obesity coverage. It was introduced with its own start date still a placeholder, and Nebraska has not enacted a requirement since.

    “No later than XXX, the department shall provide comprehensive coverage for treatment of obesity for medicaid recipients with an indication for chronic weight management to include intensive behavioral therapy and anti-obesity medication as approved by the federal Food and Drug Administration.”

    Legislature of Nebraska — Read first time January 04, 2024

Telehealth in Nebraska

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

What the state didn't publish

Nebraska has not announced a GLP-1 or weight-loss drug decision in any Medicaid provider bulletin it currently lists for 2025 or 2026.

We checked all 30 provider bulletins listed on the department's own bulletin index for 2025 and 2026, read in full in September 2026, and scanned for GLP-1, Wegovy, Zepbound, Saxenda, semaglutide, tirzepatide, liraglutide, anti-obesity, weight loss and weight management.

Among those same 30 bulletins, "dental" appears in 6, "pharmacy" in 4, "Preferred Drug List" in 2 and "prior authorization" in 2. The absence described above is limited to these 2025 and 2026 provider bulletins as read in September 2026; it does not establish what the separate coverage criteria allow.

Source: Provider Bulletin 26-10 — Changes to the Nebraska Medicaid Preferred Drug List (PDL), Nebraska Department of Health and Human Services, Division of Medicaid and Long-Term Care.

Which of these companies serve Nebraska?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

23 of those lists name Nebraska: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, ZYP Medical, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, MEDvidi, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.

Browse 50 other state guides